Radar · Life Sciences in Zhejiang
Best Life Sciences Companies in Zhejiang, China
The 123 best Life Sciences companies in Zhejiang, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ascletis.
By Rohit KhannaTrends & Stories
123companies tracked
$2.2Bdisclosed funding
1unicorns
65have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × ZHEJIANG
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2017median founding year
Ranked: Best Life Sciences companies in Zhejiang
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ascletis Developer of small molecules for the treatment of multiple diseases 42Funding top 19%Product top 30%Moat top 31%Innovation top 34% All 10 signals ▾Fundingtop 19% Producttop 30% Moattop 31% Innovationtop 34% Talentbottom 49% Marketbottom 42% Growthbottom 42% Globalbottom 36% Techbottom 30% Newsbottom 24% Funding: Raised $255M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) Product: 6 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 42/100 | $255M | 3 mo ago | Series B | Jinzi Wu Founder & CEO | 41 | PHPJW PlayerBootstrap+6 | — | — |
| 2 | Adlai Nortye Developer of immune oncolytic therapies for treating cancer | $253M | 59 mo ago | Public | Carsten Lu Founder & ceo | 27 27 → 63 (+133%) | — | 190 patents Targeted oncology therapeutics: small‑molecule degraders, kinase inhibitors, and antibody‑drug conjugates | — |
| 3 | BioRay Pharmaceutical 🦄 Developer of therapeutics for immunology and oncology | $215M | 41 mo ago | Acquired | Haibin Wang CEO | 8 | PHPNginxAOS+6 | — | — |
| 4 | RecBio Developer of vaccines to prevent infectious disease | $172M | 66 mo ago | Public | Yong Liu Founder & CEO | — | BootstrapjQuerySwiper+4 | — | — |
| 5 | Qixin Biotechnology Provider of gene-editing technology for therapies | $116M | 32 mo ago | Series A | Luhan Yang Co-Founder | — | Apple iCloud MailNode.jsVue.js+6 | — | — |
| 6 | Immorna Developer of mRNA-based therapeutics for cancer and other diseases 14Funding top 29%Moat top 38%Talent bottom 49%Global bottom 36% All 6 signals ▾Fundingtop 29% Moattop 38% Talentbottom 49% Globalbottom 36% Marketbottom 25% Techbottom 24% Funding: Raised $115M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 14/100 | $115M | 21 mo ago | Series A | Zihao Wang CEO | — | Microsoft ASP.NETBootstrapTengine+3 | — | — |
| 7 | PTM Biolab Developer of a technology platform for the discovery of biomarker, antibody, and proteomic analysis | $100M | 67 mo ago | Series B | Cheng Zhongyi CEO | 326 | — | 8 patents Epigenetic lysine PTM detection reagents and capecitabine polymer‑lipid nanocarrier delivery | — |
| 8 | Microtech Medical Medical devices developer for diabetes care | $88M | 66 mo ago | Public | — | 742 | BootstrapVideoJSGSAP+5 | 54 patents Closed-loop insulin delivery and continuous glucose monitoring biosensor technologies. | 1 partnership |
| 9 | Hangzhou Andao Pharmaceutical Developer of therapeutics for the treatment of cancer and kidney diseases | $85M | 53 mo ago | Series B | Liu Dong CEO | — | — | — | — |
| 10 | Zhejiang Dekang Medical Equipment Developer of orthopedic implants and surgical technology systems | $79M | 41 mo ago | Series B | Xiaobo Xu CEO | — | — | — | — |
| 11 | Ustar Biotechnologies Isothermal amplification kits for pathogen detection and genotyping of infectious diseases | $62M | 54 mo ago | Series E | — | 65 | WordPressMySQLPHP+21 | 31 patents Integrated microfluidic nucleic acid detection platforms for rapid CRISPR‑based diagnostics | — |
| 12 | Novocodex Biopharmaceuticals Developer of antibodies for treating cancer | $61M | 63 mo ago | Series A | Wang Yongzhong CEO | 104 | — | 25 patents Site-specific incorporation of unnatural amino acids into therapeutic proteins and conjugates | — |
| 13 | Worg Developer of treatments for allergic and autoimmune diseases | $57M | 45 mo ago | Series B | — | 40 | Animate.cssBootstrapTengine+3 | — | — |
| 14 | Zenshine Pharmaceuticals Developer of small molecules drug for the treatment of cancer | $52M | 60 mo ago | Series A | Jinfu Yang Co-Founder | — | — | 20 patents Antiviral influenza agents and PI3Kα inhibitor therapeutics for oncology | — |
| 15 | Ranok Therapeutics Developer of novel therapeutics for the treatment of cancer | $50M | 58 mo ago | Series B | Weiwen Ying Founder & CEO | — | — | 77 patents KRAS G12D/G12V mutant inhibitors and targeted protein degradation therapeutics | — |
| 16 | Health Gene Technologies Provider of DNA testing solutions for diagnostic solutions | $48M | 46 mo ago | Series C | — | 33 | — | — | — |
| 17 | Yunhu Technology Group Provider of DNA testing services | $38M | 81 mo ago | Series A | Chen Xiaobing CEO | 1,200 | — | 4 patents Minimally invasive surgical and injection devices for gastrointestinal and reconstructive procedures | — |
| 18 | Venus MedTech Transcatheter aortic valves | $37M | 97 mo ago | Public | Eric Zi Founder & CEO | 1,006 | PHPWindows ServerUIKit+6 | 354 patents Patents concentrated in health & consumer products | — |
| 19 | Chance Pharmaceuticals Developer of transformative inhalation therapies for pulmonology disorders 37Talent top 28%Funding top 41%Global bottom 38%Market bottom 37% All 5 signals ▾Talenttop 28% Fundingtop 41% Globalbottom 38% Marketbottom 37% Newsbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $31.0M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $31M | 15 mo ago | Series C | Peng Huang Co-Founder | — | — | — | — |
| 20 | RoboCT Technology Digital platform focusing on rehabilitation and elderly care by combining human-computer interactions 50Funding top 36%Market top 42%Growth top 45%Talent bottom 49% All 6 signals ▾Fundingtop 36% Markettop 42% Growthtop 45% Talentbottom 49% Globalbottom 48% Techbottom 35% Funding: Raised $29.4M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Market: 100 employees (top 20% of Life Sciences) · Top-5,000,000 web property rank vs industry peers · Fliar Intelligence Index 50/100 | $29M | 3 mo ago | Series B | Wang Tian Founder & CEO | 100 | Cart FunctionalityPHPLayui+13 | — | 1 partnership |
| 21 | Hangzhou Lianchuan Biotechnology Provider of genetic testing services | $26M | 56 mo ago | Series B | — | 271 | — | — | — |
| 22 | Mozhuo Biotechnology Developer of microfluidic technology for diagnosis and research | $23M | 46 mo ago | Series A | Pei Hao Founder & CEO | — | — | — | — |
| 23 | Hangzhou Shuyang Biotechnology Developer of therapeutic antibodies and recombinant protein drugs | $20M | 46 mo ago | Series B | — | 180 | — | — | — |
| 24 | Zhejiang Norcong Neuroelectronics Developer of ear implant and speech processing devices | $16M | 68 mo ago | Series B | Chu Li CEO | — | WordPressMySQLPHP+8 | — | — |
| 25 | ThunderBio Innovation Developer of microfluidic technology for diagnosis and research | $15M | 29 mo ago | Series B | Joseph Chow Co-Founder & CEO | — | — | — | — |
| 26 | M20 Genomics Developer of single-cell products and related technologies | $15M | 49 mo ago | Seed | Yongcheng Wang Co-Founder & CTO | — | — | — | 2 launchs |
| 27 | Qiyuan Biological Developer of drugs for the treatment of autoimmune diseases 22Funding top 41%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 41% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $14.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $14M | 9 mo ago | Series B | Ding Shizhe CEO | — | — | — | — |
| 28 | Hangzhou Kaibao Biotechnology Developer of drugs for treating cancer | $14M | 71 mo ago | Series B | Sun Jianhua CEO | — | — | — | — |
| 29 | SynRx Therapeutics Developer of targeted cancer chemotherapy drugs | $14M | 43 mo ago | Seed | Xiaochun Yu Co-Founder | — | — | 18 patents Design and synthesis of fused nitrogen heterocycles as DNA repair enzyme inhibitors | — |
| 30 | Junhemeng Biopharmaceutical Developer of recombinant protein drugs for endocrine and metabolic fields | $14M | 25 mo ago | Series B | — | — | — | — | — |
| 31 | Celgenyx Developer of cellular immune products for the treatment of malignant tumors | $14M | 43 mo ago | Series A | Ken Ren CEO | — | — | — | — |
| 32 | Hangzhou Tongee Medical Technology Limited information available | $9M | 48 mo ago | Series B | — | 90 | — | — | — |
| 33 | Polymed Biopharmaceuticals Developer of small molecule therapeutics for cancer and autoimmune diseases | $8M | 58 mo ago | Seed | Jason Xiang Founder & CEO | — | — | 47 patents Patents concentrated in chemistry & materials | — |
| 34 | AIxplorerBio AI-based drug development tool for providers | $8M | 61 mo ago | Series A | David Xu Founder & CEO | — | — | — | — |
| 35 | Suzhou Yihe Pharmaceutical Developer of dry powder inhalers | $7M | 32 mo ago | Series A | Jingxu Zhu Founder | — | — | — | — |
| 36 | Medlinkbci Provider of brain-computer interface active rehabilitation device | $4M | 58 mo ago | Late Stage | — | 50 | — | — | — |
| 37 | Nanochap Bio-medical devices developer 69Talent top 35%Market top 39%Funding top 42%Global bottom 36% All 4 signals ▾Talenttop 35% Markettop 39% Fundingtop 42% Globalbottom 36% Talent: Analyst team rating 4/5 · 2 named leaders on record Market: 100 employees (top 25% of High Tech) rank vs industry peers · Fliar Intelligence Index 69/100 | $4M | 1 mo ago | Series B | Jiawei Yang Co-Founder & CEO | 100 | — | — | 1 job opening |
| 38 | Doouya Health management tools for infants | $2M | 130 mo ago | Deadpooled | Prasun Sarkar Founder & CEO | — | — | — | — |
| 39 | Puyuan Biotech Developer of microbial drugs for immune diseases | $1M | 41 mo ago | Seed | — | — | — | — | — |
Top 12 Life Sciences companies in Zhejiang
#1
Series B · Hangzhou, Zhejiang · founded 2011 · 41 employees$255Mraised▾
Series B · Hangzhou, Zhejiang · founded 2011 · 41 employees
Developer of small molecules for the treatment of multiple diseases. It offers pipeline of drug candidates which include Ritonavir for Covid, Ravidasvir for HCV, ASC22 for HIV, ASC40 for NASH, acne, solid tumor, breast cancer, and others.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 19%Product
top 30%Moat
top 31%Innovation
top 34%Talent
bottom 49%Market
bottom 42%Funding: Raised $255M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) · Last round Post IPO (Feb 2026)
Product: 6 distinct product lines · Company stage: Series B
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Feb 2026Post IPO$107.9M
- Jan 2017Series B$100M
- Dec 2015Series B$20M
- Sep 2015Series B$35M
Founders & team
Investors
CBC Group, Tasly, Pavilion Capital Partners, Goldman Sachs, Qianhai Equity Investment Fund, Hangzhou Binjiang Investment Holding
#2
Series B · Hangzhou, Zhejiang · founded 2017 · 100 employees$29.4Mraised▾
Series B · Hangzhou, Zhejiang · founded 2017 · 100 employees
Digital platform focusing on rehabilitation and elderly care by combining human-computer interactions. The company's products include exoskeleton robotics, robot joint modules, mecanum wheel modules, and servo motion control solutions. It also operate a rehabilitation cloud platform that supports remote rehabilitation guidance and a rehabilitation intelligence evaluation system that generates detailed assessment reports for users to track progress and effectiveness.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 36%Market
top 42%Growth
top 45%Talent
bottom 49%Global
bottom 48%Tech
bottom 35%Funding: Raised $29.4M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series B (Mar 2026)
Market: 100 employees (top 20% of Life Sciences) · Top-5,000,000 web property
Growth: Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 360 LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. Grupo Laços and the China Trade Center Group) announced in 12 mo
Funding rounds
- Mar 2026Series B$13.7M
- Feb 2022Series A$15.7M
- Mar 2021Seed—
Founders & team
Investors
Lanchi Venture Capital, Poly Development Holdings, Anxin Securities, Fortune Capital, Asia Business Capital, Hangzhou Capital
Tech stack
Baidu Analytics (百度统计)Cart FunctionalityFont AwesomeFullpage.JsGoogle AnalyticsGoogle Tag Manager
#3
Series B · Hangzhou, Zhejiang · founded 2014 · 100 employees$3.8Mraised▾
Series B · Hangzhou, Zhejiang · founded 2014 · 100 employees
Nanochap is a bio-medical device developer. Some of its devices include neural stimulator, blood pressure measurement, portable pain relief management. The company has developed the NanoHug, blood pressure measuring device, uses the electronic blood pressure measurement technology. The device contains a sensor for measuring diastolic blood pressure, systolic blood pressure, heart rate, and the pulse image of the human body.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Talent
top 35%Market
top 39%Funding
top 42%Global
bottom 36%Talent: Analyst team rating 4/5 · 2 named leaders on record
Market: 100 employees (top 25% of High Tech)
Funding: Raised $3.8M across 2 rounds · 2 rounds over 10 yrs (0.2/yr) · Last round Series B (May 2026)
Audience (LinkedIn): 4k LinkedIn followers — 23.2% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum -1 · hiring: IC designers, Fireware/Hardware Engineers
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- May 2026Series B$43.9M
- Dec 2016Series A$3.8M
Founders & team
Investors
Jiayuan Fund, Legend Capital, Harvest Capital, GF Securities, Caitong Capital, Tai Partners
#4
Series B · Hangzhou, Zhejiang · founded 2020$14.5Mraised▾
Series B · Hangzhou, Zhejiang · founded 2020
Developer of drugs for the treatment of autoimmune diseases. The lead candidate of the company includes "QY101" a non-hormonal and non-steroidal anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor for Atopic dermatitis. Other drug candidates include QY211 for psoriasis, QY301 for ulcerative colitis, Crohn's disease, and QY401 for respiratory-related indications.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 41%Talent
bottom 49%Market
bottom 37%Global
bottom 29%Funding: Raised $14.5M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Sep 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Sep 2025Series B$28M
- Aug 2022Series A$14.5M
Founders & team
Investors
Taikuncompanies, Shijie Investment, Linping Guotou, Hangzhou Jintou Industrial Fund, FuZhe Fund, HLC
#5
Series A · Hangzhou, Zhejiang · founded 2019$115Mraised▾
Series A · Hangzhou, Zhejiang · founded 2019
Developer of mRNA-based therapeutics for cancer and other diseases. It offers mRNA delivery vehicles including polymers and lipid nanoparticles for intramuscular, intravenous, and tissue-targeting delivery. It has developed a pipeline for cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology.
Fliar Intelligence Index™ 14how this company ranks against its industry peers
Funding
top 29%Moat
top 38%Talent
bottom 49%Global
bottom 36%Market
bottom 25%Tech
bottom 24%Funding: Raised $115M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Grant (prize money) (Aug 2024)
Moat: Editorial + unicorn rating 5/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Aug 2024Grant (prize money)—
- Feb 2023Series A$100M
- Feb 2021Series A$15M
Founders & team
Investors
China Growth Capital, Guangzhou Yuexiu Industrial Investment Fund Management, Hillhouse, Co-win Ventures, ZSVC, TigerYeah Capital
#6
Series C · Hangzhou, Zhejiang · founded 2015$31Mraised▾
Series C · Hangzhou, Zhejiang · founded 2015
Developer of transformative inhalation therapies for pulmonology disorders. The company's lead candidate CXF11 is a tiotropium bromide inhalation drug for the prevention of bronchospasm in patients with chronic obstructive pulmonary disease. Also, developing an inhaler to disperse powder and deliver particles to the lung.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Talent
top 28%Funding
top 41%Global
bottom 38%Market
bottom 37%News
bottom 18%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $31.0M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) · Last round Series C (Mar 2025)
Global: Investors from 3 countries beyond China
Funding rounds
- Mar 2025Series C—
- Jan 2022Series C—
- Oct 2021Series C$31M
Founders & team
Investors
Fortune Capital, China Merchants Securities, Heda Capital, Shenzhen Guozhong Venture Capital Management, Long Rock Capital, HEDA Ventures
#7
Series A · Hangzhou, Zhejiang · founded 2017$116Mraised▾
Series A · Hangzhou, Zhejiang · founded 2017
Provider of gene-editing technology for therapies. The company uses this platform of genetic engineering for developing tools for organ transplantation and regenerative medicines. It uses CRISPR/Cas9 system as a gene-editing tool.
Funding rounds
- Sep 2023Series A$16M
- Mar 2021Series A$67M
- Sep 2019Series A$22.5M
- Jul 2018Series A$7.8M
Founders & team
Investors
CMB International Capital, Legend Star, BC Capital, Sequoia Capital, NLVC, Arch Venture Partners
Tech stack
Apple Icloud MailCore-JsNode.JsNuxt.JsOpen GraphSwiper
#8
Acquired · Taizhou, Zhejiang · founded 2019 · 8 employees$215Mraised▾
Acquired · Taizhou, Zhejiang · founded 2019 · 8 employees
Developer of therapeutics for immunology and oncology. It offers antibody-technology platform for the development of therapeutics for immune-mediated diseases including rheumatoid arthritis, psoriasis, and Ankylosing Spondylitis. It also offers drugs for cancer and tumors. Company offers formulated products made from organic ingredients that restore health and promote balance in the body.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers — 6.7% of this cohort's audience
Funding rounds
- Dec 2022Series D$215M
Founders & team
Tech stack
AosFont AwesomeHstsHttp/3JqueryJquery Migrate
#9
Public · Hangzhou, Zhejiang · founded 2014 · 27 employees$253Mraised▾
Public · Hangzhou, Zhejiang · founded 2014 · 27 employees
Developer of immune oncolytic therapies for treating cancer. The company's lead product, REOLYSIN is used for treating breast cancer. It selectively lyses tumors and activates the innate and adaptive immune systems. Other candidates of the company include AN0025 (for solid tumors), AN0015 & AN3005 (for multiple tumors).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers — 10.5% of this cohort's audience
Funding rounds
- Jul 2021Series D$100M
- Aug 2020Series C$100M
- Jun 2018Series B$53M
Founders & team
Investors
SDIC, Triwise Capital, WuXi Biologics, Guolian Securities Co, Tian Ge, Legend Star
#10
Series B · Jiaxing, Zhejiang · founded 2015$79Mraised▾
Series B · Jiaxing, Zhejiang · founded 2015
Developer of orthopedic implants and surgical technology systems. The company offers a full range of implant products, surgical planning, and surgical assistance solutions. Also, it offers spinal internal fixation systems, artificial hip and knee replacement systems, trauma series, sports medicine, and other series.
Funding rounds
- Dec 2022Series B—
- Feb 2022Series B$79M
Founders & team
Investors
Lanshan Investment, Zhejiang Haibang Investment Management, JunHe, Jiaxin Silk, Bojiang Capital, Yonggui Electric
#11
Series B · Hangzhou, Zhejiang$13.8Mraised▾
Series B · Hangzhou, Zhejiang
Developer of recombinant protein drugs for endocrine and metabolic fields
Investors
Tonghua Dongbao Pharma
#12
Public · Taizhou, Zhejiang · founded 2012$171.8Mraised▾
Public · Taizhou, Zhejiang · founded 2012
Developer of vaccines to prevent infectious disease. The company's products include recombinant COVID-19 vaccine, coronary pneumonia vaccine (CHO cell) ReCOV, Human Papillomavirus Vaccine (Nine/Bivalent) to prevent HPV-induced infections, and recombinant shingles vaccine to prevent the infraction caused by the varicella-zoster virus (VZV).
Funding rounds
- Dec 2020Series B$100M
- 2019Series A$71.8M
Founders & team
Investors
Legend Capital, LYFE Capital, Vertex Ventures, Haitong Kaiyuan Investment, Yuanbio Venture Capital, China Everbright
Funding & investor landscape
$2.2Btotal disclosed funding
39companies funded
59disclosed rounds
1rounds last 90 days
Most active investors
Qiming Venture Partners7 rounds
Notable founders
Jinzi Wu
Founder & CEO · Ascletis
Wang Tian
Founder & CEO · RoboCT Technology
Jiawei Yang
Co-Founder & CEO · Nanochap
Nhan Tran
Co-Founder & CTO · Nanochap
Ding Shizhe
CEO · Qiyuan Biological
Zihao Wang
CEO · Immorna
Peng Huang
Co-Founder · Chance Pharmaceuticals
Guobao Zhao
Co-Founder & SVP · Chance Pharmaceuticals
Luhan Yang
Co-Founder · Qixin Biotechnology
George Church
Co-Founder · Qixin Biotechnology
Haibin Wang
CEO · BioRay Pharmaceutical
Carsten Lu
Founder & ceo · Adlai Nortye
Prism market signals · China · country-scoped Prism corpus, 217,045 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN ZHEJIANG · Health & Bio
How research on Biotechnology in Zhejiang is moving
A read on the academic research around Biotechnology in Zhejiang — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 287 papers.
Zhejiang University and agricultural partners lead mostly optimistic research on plant-microbe interactions, gene expression, and CRISPR, with growing pharmaceutical environmental concern.
287 papers · stance +0.49 · 33% breakthrough · 17% concern
top institutions
- Zhejiang University110
- ZheJiang Academy of Agricultural Sciences36
- Zhejiang A & F University26
- First Affiliated Hospital Zhejiang University21
- Zhejiang University of Technology18
leading researchers
Ying Liu · Lei Zhou · Xin Wang · Yuehua Chen · Bin Wang · Binglin Shen
prism intelligence · tone & topics
92% positive · 5% critical tone
HealthAgricultureMedical ResearchPharmaceuticalsBiologyGenetics
▲
Breakthroughs85 · 30%
▼ 75%→28% share
▼0.4× share momentum0 median citations87% since 2021mostly methods-led
Metabolomics and histone research newly emerging in Zhejiang biotech breakthroughs, while gene-focused papers surged 1→12.
rising sub-themes (early→recent)
- Gene1→12
- Transcription factor1→7
Newly emergingMetabolomics 0→5 · Histone 0→4 · DNA damage 0→4
Landmark VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenyl · 953 cites
◆
Advancements129 · 45%
▲ 25%→46% share
▲1.8× share momentum0 median citations91% since 2021mostly empirical
Advancements intensifying — field-share nearly doubled 25→46%, with gene knockdown and apoptosis newly emerging at 6 papers each.
rising sub-themes (early→recent)
- Gene1→13
Newly emergingDownregulation and upregulation 0→6 · Apoptosis 0→6 · Gene knockdown 0→6
Landmark Applications of Nanotechnology in Plant Growth and Crop Protection: A Review · 1,188 cites
▼
Concerns44 · 15%
▲ 0%→15% share
0 median citations93% since 2021mostly reviews
Biosafety concerns newly emerging — antibiotic resistance and human health topics both debuted at 4 papers, virulence at 3.
rising sub-themes (early→recent)
- Antibiotic resistance4
- Human health4
- Abiotic stress3
- Virulence3
- Antibiotics3
Newly emergingAntibiotic resistance 0→4 · Human health 0→4 · Virulence 0→3
Landmark Polyamine Function in Plants: Metabolism, Regulation on Development, and Roles in Abiotic Stress Responses · 838 cites
Common questions
How many Life Sciences companies are there in Zhejiang, China?
Radar tracks 123 indexable Life Sciences companies headquartered in Zhejiang, China that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Zhejiang, China?
The Life Sciences companies in Zhejiang, China on this list have raised a combined $2.2B in disclosed equity funding across 39 funded companies.
Which is the highest-funded Life Sciences company in Zhejiang, China?
Ascletis is the highest-funded Life Sciences company in Zhejiang, China, with $255M in disclosed equity funding.
How many Life Sciences companies in Zhejiang, China are funded?
39 of the 123 Life Sciences companies in Zhejiang, China on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Zhejiang, China?
1 Life Sciences company in Zhejiang, China on this list is valued at $1B or more.
Who are the top investors in Zhejiang, China Life Sciences companies?
The most active investors in Zhejiang, China Life Sciences companies on this list include CD Capital, Qiming Venture Partners, Proxima Ventures, Huagai Capital, Legend Capital.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.